---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-206255"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:35:39.502015+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Soleno completes enrollment in PWS Study C602; Q2 net loss $8.5M

## Summary
- Completed enrollment in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.
- Top-line data expected around end of Q3 2023; could support NDA submission to FDA.
- Received $10M from SPA warrant exercise; cash and equivalents $19.4M as of June 30, 2023.
- Net loss for Q2 2023 was $8.5M ($0.81 per share) vs $6.7M ($0.72 per share) in Q2 2022.
- R&D expenses $5.1M in Q2 2023, up from $3.7M year-over-year due to clinical progress.

## SEC filing metadata
- accession: 0001193125-23-206255
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312523206255/0001193125-23-206255-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312523206255/d452584d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-206255
- JSON: https://secwatch.observer/filing/0001193125-23-206255.json
- Plain text: https://secwatch.observer/filing/0001193125-23-206255.txt

## Key facts
- Earnings Releases
  SOLENO THERAPEUTICS INC reported the second quarter ended June 30, 2023 results: net income $8.5 million, EPS $0.81.
  - Period: the second quarter ended June 30, 2023
  - Net income: $8.5 million
  - EPS: $0.81
  - Result: reported results
  source text: Net loss for the three and six months ended June 30, 2023, was $8.5 million and $16.8 million, or a net loss of $0.81 and $1.69 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484565/000119312523206255/0001193125-23-206255-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.